Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alopecia | 23 | 2020 | 29 | 8.210 |
Why?
|
| African Americans | 22 | 2020 | 1335 | 3.400 |
Why?
|
| Skin Pigmentation | 10 | 2020 | 27 | 3.150 |
Why?
|
| Scalp Dermatoses | 8 | 2021 | 18 | 2.850 |
Why?
|
| Hair | 9 | 2019 | 27 | 2.810 |
Why?
|
| Scalp | 10 | 2020 | 35 | 2.540 |
Why?
|
| Hair Preparations | 12 | 2020 | 12 | 2.490 |
Why?
|
| Alopecia Areata | 14 | 2020 | 16 | 2.410 |
Why?
|
| Cicatrix | 8 | 2020 | 39 | 2.100 |
Why?
|
| Lichen Planus | 5 | 2021 | 10 | 1.980 |
Why?
|
| Dermatology | 8 | 2020 | 157 | 1.780 |
Why?
|
| Minoxidil | 5 | 2017 | 6 | 1.600 |
Why?
|
| Hyperpigmentation | 8 | 2018 | 17 | 1.540 |
Why?
|
| Humans | 89 | 2021 | 32286 | 1.490 |
Why?
|
| Skin Diseases | 4 | 2020 | 135 | 1.460 |
Why?
|
| Dermatologic Agents | 11 | 2020 | 233 | 1.290 |
Why?
|
| Acne Vulgaris | 7 | 2019 | 101 | 1.180 |
Why?
|
| Ethnic Groups | 7 | 2020 | 450 | 1.150 |
Why?
|
| Hair Removal | 4 | 2012 | 5 | 1.130 |
Why?
|
| African Continental Ancestry Group | 7 | 2017 | 338 | 1.110 |
Why?
|
| Middle Aged | 34 | 2020 | 11848 | 1.050 |
Why?
|
| Adult | 34 | 2020 | 9263 | 1.030 |
Why?
|
| Female | 46 | 2020 | 19955 | 1.030 |
Why?
|
| Severity of Illness Index | 14 | 2020 | 854 | 0.930 |
Why?
|
| Patient Satisfaction | 5 | 2016 | 230 | 0.920 |
Why?
|
| Glucocorticoids | 5 | 2020 | 146 | 0.890 |
Why?
|
| European Continental Ancestry Group | 6 | 2019 | 1076 | 0.840 |
Why?
|
| Cultural Diversity | 3 | 2020 | 17 | 0.820 |
Why?
|
| Internship and Residency | 3 | 2020 | 317 | 0.810 |
Why?
|
| Psoriasis | 3 | 2019 | 355 | 0.800 |
Why?
|
| Laser Therapy | 5 | 2012 | 51 | 0.770 |
Why?
|
| Skin | 4 | 2019 | 213 | 0.760 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 161 | 0.680 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2021 | 5 | 0.670 |
Why?
|
| Hair Diseases | 3 | 2007 | 4 | 0.670 |
Why?
|
| Photochemotherapy | 1 | 2021 | 14 | 0.660 |
Why?
|
| Dermoscopy | 1 | 2020 | 12 | 0.640 |
Why?
|
| Triamcinolone Acetonide | 1 | 2020 | 4 | 0.620 |
Why?
|
| Exercise | 2 | 2016 | 605 | 0.620 |
Why?
|
| Delusions | 1 | 2019 | 3 | 0.610 |
Why?
|
| Psychophysiologic Disorders | 1 | 2019 | 5 | 0.610 |
Why?
|
| Lasers, Solid-State | 3 | 2020 | 8 | 0.610 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 388 | 0.600 |
Why?
|
| Hypopigmentation | 1 | 2019 | 7 | 0.600 |
Why?
|
| Pityriasis Lichenoides | 1 | 2019 | 4 | 0.600 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 293 | 0.600 |
Why?
|
| Continental Population Groups | 3 | 2020 | 228 | 0.600 |
Why?
|
| Forehead | 2 | 2019 | 11 | 0.590 |
Why?
|
| Dietary Supplements | 2 | 2017 | 189 | 0.580 |
Why?
|
| Skin Diseases, Viral | 1 | 2019 | 4 | 0.580 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2019 | 4 | 0.580 |
Why?
|
| Herpes Zoster | 1 | 2019 | 12 | 0.570 |
Why?
|
| United States | 16 | 2020 | 4077 | 0.570 |
Why?
|
| Young Adult | 11 | 2018 | 2652 | 0.560 |
Why?
|
| Quality of Life | 7 | 2019 | 970 | 0.560 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 245 | 0.560 |
Why?
|
| Radiotherapy | 1 | 2018 | 92 | 0.550 |
Why?
|
| Occupational Exposure | 2 | 2016 | 159 | 0.550 |
Why?
|
| Parabens | 1 | 2018 | 1 | 0.540 |
Why?
|
| Sulfates | 1 | 2018 | 4 | 0.540 |
Why?
|
| Treatment Outcome | 12 | 2020 | 3409 | 0.530 |
Why?
|
| Dermatitis, Atopic | 1 | 2019 | 103 | 0.530 |
Why?
|
| Male | 28 | 2019 | 19448 | 0.530 |
Why?
|
| Barbering | 2 | 2017 | 2 | 0.530 |
Why?
|
| Hygiene | 2 | 2015 | 9 | 0.520 |
Why?
|
| Hispanic Americans | 4 | 2016 | 772 | 0.520 |
Why?
|
| Adjuvants, Immunologic | 2 | 2010 | 61 | 0.510 |
Why?
|
| Vitamins | 1 | 2017 | 70 | 0.500 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 212 | 0.490 |
Why?
|
| Health Education | 1 | 2017 | 149 | 0.490 |
Why?
|
| Adolescent | 14 | 2019 | 3519 | 0.480 |
Why?
|
| Keloid | 2 | 2013 | 8 | 0.480 |
Why?
|
| Skin Care | 1 | 2016 | 12 | 0.480 |
Why?
|
| Pigmentation Disorders | 2 | 2014 | 8 | 0.470 |
Why?
|
| Biological Products | 1 | 2017 | 79 | 0.470 |
Why?
|
| Beauty | 2 | 2013 | 5 | 0.460 |
Why?
|
| Research Design | 2 | 2017 | 316 | 0.460 |
Why?
|
| Plant Extracts | 1 | 2016 | 61 | 0.460 |
Why?
|
| Asian Continental Ancestry Group | 2 | 2014 | 101 | 0.430 |
Why?
|
| Cosmetic Techniques | 2 | 2017 | 11 | 0.430 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 220 | 0.430 |
Why?
|
| Cross-Sectional Studies | 6 | 2020 | 1485 | 0.420 |
Why?
|
| Foot Diseases | 1 | 2014 | 9 | 0.410 |
Why?
|
| Urea | 1 | 2014 | 38 | 0.410 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 595 | 0.410 |
Why?
|
| Lasers, Excimer | 1 | 2013 | 7 | 0.400 |
Why?
|
| Keratins, Hair-Specific | 1 | 2013 | 1 | 0.390 |
Why?
|
| Formaldehyde | 1 | 2013 | 15 | 0.390 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 501 | 0.380 |
Why?
|
| Child | 8 | 2018 | 2432 | 0.370 |
Why?
|
| Lip | 1 | 2012 | 7 | 0.370 |
Why?
|
| Lice Infestations | 1 | 2011 | 1 | 0.350 |
Why?
|
| Biopsy | 4 | 2019 | 249 | 0.350 |
Why?
|
| Health Behavior | 1 | 2013 | 213 | 0.340 |
Why?
|
| Neoplasms | 1 | 2018 | 762 | 0.340 |
Why?
|
| Administration, Topical | 5 | 2020 | 142 | 0.330 |
Why?
|
| Aged | 13 | 2016 | 10259 | 0.320 |
Why?
|
| Osteoma | 1 | 2010 | 1 | 0.320 |
Why?
|
| Injections, Intralesional | 3 | 2020 | 16 | 0.320 |
Why?
|
| Facial Neoplasms | 1 | 2010 | 9 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 545 | 0.320 |
Why?
|
| Aminoquinolines | 1 | 2010 | 18 | 0.310 |
Why?
|
| Palate | 1 | 2009 | 4 | 0.290 |
Why?
|
| Hypertrichosis | 1 | 2009 | 3 | 0.290 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 317 | 0.280 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2008 | 5 | 0.280 |
Why?
|
| Surgical Flaps | 1 | 2009 | 75 | 0.280 |
Why?
|
| Isotretinoin | 3 | 2016 | 13 | 0.270 |
Why?
|
| Phototherapy | 3 | 2020 | 50 | 0.270 |
Why?
|
| Hot Temperature | 1 | 2007 | 81 | 0.260 |
Why?
|
| Photography | 3 | 2017 | 42 | 0.260 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2009 | 191 | 0.250 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2020 | 115 | 0.250 |
Why?
|
| Postoperative Complications | 1 | 2012 | 818 | 0.250 |
Why?
|
| Dermatitis, Seborrheic | 2 | 2017 | 4 | 0.240 |
Why?
|
| Melanosis | 3 | 2020 | 14 | 0.240 |
Why?
|
| Rosacea | 2 | 2017 | 46 | 0.220 |
Why?
|
| Cosmetics | 3 | 2019 | 11 | 0.220 |
Why?
|
| Irritants | 1 | 2004 | 2 | 0.210 |
Why?
|
| Retrospective Studies | 4 | 2020 | 3612 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Data Collection | 3 | 2017 | 171 | 0.210 |
Why?
|
| Sunscreening Agents | 2 | 2019 | 12 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.200 |
Why?
|
| Age Factors | 3 | 2020 | 1178 | 0.200 |
Why?
|
| Health Care Surveys | 3 | 2015 | 184 | 0.200 |
Why?
|
| Sex Factors | 4 | 2015 | 656 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Immunologic Factors | 1 | 2003 | 53 | 0.190 |
Why?
|
| Administration, Oral | 2 | 2020 | 200 | 0.190 |
Why?
|
| Double-Blind Method | 4 | 2019 | 567 | 0.190 |
Why?
|
| Comorbidity | 3 | 2014 | 563 | 0.190 |
Why?
|
| Child, Preschool | 3 | 2014 | 1234 | 0.180 |
Why?
|
| Skin Ulcer | 1 | 2002 | 12 | 0.180 |
Why?
|
| Herpes Simplex | 1 | 2002 | 14 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2002 | 19 | 0.180 |
Why?
|
| Erythema | 1 | 2002 | 25 | 0.180 |
Why?
|
| Office Visits | 2 | 2015 | 71 | 0.170 |
Why?
|
| Prevalence | 3 | 2019 | 955 | 0.170 |
Why?
|
| Aminolevulinic Acid | 1 | 2021 | 8 | 0.170 |
Why?
|
| Case-Control Studies | 3 | 2016 | 854 | 0.170 |
Why?
|
| Photosensitizing Agents | 1 | 2021 | 16 | 0.170 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2020 | 4 | 0.170 |
Why?
|
| Injections, Intradermal | 1 | 2020 | 8 | 0.160 |
Why?
|
| Physician-Patient Relations | 2 | 2012 | 179 | 0.160 |
Why?
|
| Risk Factors | 5 | 2016 | 3937 | 0.160 |
Why?
|
| Bibliometrics | 1 | 2020 | 11 | 0.160 |
Why?
|
| Hypochondriasis | 1 | 2019 | 1 | 0.150 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2019 | 2 | 0.150 |
Why?
|
| S100 Proteins | 1 | 2019 | 20 | 0.150 |
Why?
|
| Drug Compounding | 2 | 2018 | 36 | 0.150 |
Why?
|
| Publishing | 1 | 2020 | 66 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 27 | 0.150 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2018 | 6 | 0.140 |
Why?
|
| Methotrexate | 1 | 2019 | 70 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 248 | 0.140 |
Why?
|
| North Carolina | 4 | 2016 | 1300 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 442 | 0.140 |
Why?
|
| Dapsone | 1 | 2018 | 5 | 0.140 |
Why?
|
| Infant | 2 | 2014 | 1010 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 46 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 411 | 0.130 |
Why?
|
| Cultural Competency | 1 | 2017 | 15 | 0.130 |
Why?
|
| Internet | 2 | 2018 | 202 | 0.130 |
Why?
|
| Administration, Cutaneous | 3 | 2015 | 116 | 0.130 |
Why?
|
| Disease Progression | 1 | 2019 | 591 | 0.130 |
Why?
|
| Vaccination | 1 | 2019 | 155 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 821 | 0.120 |
Why?
|
| Demography | 1 | 2017 | 101 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 325 | 0.120 |
Why?
|
| Mutation | 1 | 2019 | 497 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2009 | 120 | 0.120 |
Why?
|
| Keratolytic Agents | 3 | 2005 | 29 | 0.120 |
Why?
|
| Pharmaceutical Solutions | 1 | 2016 | 2 | 0.120 |
Why?
|
| Finasteride | 1 | 2016 | 4 | 0.120 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 20 | 0.120 |
Why?
|
| Off-Label Use | 1 | 2016 | 14 | 0.120 |
Why?
|
| Constipation | 1 | 2016 | 12 | 0.120 |
Why?
|
| Hydroquinones | 2 | 2014 | 7 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2017 | 187 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 90 | 0.120 |
Why?
|
| Decision Making | 1 | 2018 | 190 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2017 | 128 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 312 | 0.110 |
Why?
|
| Facial Dermatoses | 2 | 2006 | 18 | 0.110 |
Why?
|
| Cellulitis | 1 | 2015 | 12 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 395 | 0.110 |
Why?
|
| Deafness | 1 | 2014 | 1 | 0.100 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2014 | 1 | 0.100 |
Why?
|
| Acne Keloid | 1 | 2014 | 2 | 0.100 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2014 | 17 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 1081 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2014 | 666 | 0.100 |
Why?
|
| Retinoids | 1 | 2014 | 42 | 0.100 |
Why?
|
| Educational Status | 2 | 2011 | 168 | 0.100 |
Why?
|
| Triamcinolone | 1 | 2013 | 12 | 0.100 |
Why?
|
| Incidence | 2 | 2007 | 1243 | 0.090 |
Why?
|
| Pruritus | 1 | 2012 | 46 | 0.090 |
Why?
|
| Sensory Receptor Cells | 1 | 2012 | 35 | 0.090 |
Why?
|
| Vasodilator Agents | 2 | 2015 | 62 | 0.090 |
Why?
|
| Lasers, Semiconductor | 1 | 2011 | 1 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2012 | 111 | 0.080 |
Why?
|
| Time Factors | 1 | 2016 | 2203 | 0.080 |
Why?
|
| Caregivers | 1 | 2012 | 114 | 0.080 |
Why?
|
| Ointments | 1 | 2010 | 23 | 0.080 |
Why?
|
| Keratosis, Actinic | 1 | 2010 | 20 | 0.080 |
Why?
|
| Prognosis | 2 | 2004 | 1529 | 0.080 |
Why?
|
| Algorithms | 1 | 2012 | 536 | 0.070 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2009 | 1 | 0.070 |
Why?
|
| Pharyngectomy | 1 | 2009 | 2 | 0.070 |
Why?
|
| Oropharynx | 1 | 2009 | 9 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 550 | 0.070 |
Why?
|
| Sunlight | 2 | 2005 | 17 | 0.070 |
Why?
|
| Tretinoin | 2 | 2005 | 33 | 0.070 |
Why?
|
| Bone Diseases | 1 | 2008 | 15 | 0.070 |
Why?
|
| Mexico | 1 | 2007 | 47 | 0.070 |
Why?
|
| Microscopy | 1 | 2007 | 28 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2007 | 245 | 0.070 |
Why?
|
| Stress, Mechanical | 1 | 2007 | 96 | 0.070 |
Why?
|
| Anthralin | 1 | 2007 | 2 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 2238 | 0.060 |
Why?
|
| PUVA Therapy | 1 | 2007 | 22 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 2007 | 19 | 0.060 |
Why?
|
| Patients | 1 | 2007 | 46 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2007 | 91 | 0.060 |
Why?
|
| Women | 1 | 2006 | 12 | 0.060 |
Why?
|
| Ornithine Decarboxylase | 1 | 2005 | 1 | 0.060 |
Why?
|
| Dermabrasion | 1 | 2004 | 2 | 0.050 |
Why?
|
| Skin Aging | 1 | 2005 | 9 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 48 | 0.050 |
Why?
|
| Dinitrochlorobenzene | 1 | 2004 | 1 | 0.050 |
Why?
|
| Cyclobutanes | 1 | 2004 | 2 | 0.050 |
Why?
|
| Cryosurgery | 1 | 2004 | 25 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2004 | 13 | 0.050 |
Why?
|
| Folliculitis | 1 | 2004 | 1 | 0.050 |
Why?
|
| Antigens, CD1 | 1 | 2004 | 2 | 0.050 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2004 | 4 | 0.050 |
Why?
|
| Inflammation | 2 | 2004 | 507 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 47 | 0.050 |
Why?
|
| Prednisone | 1 | 2004 | 69 | 0.050 |
Why?
|
| Hirsutism | 1 | 2003 | 1 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 174 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2004 | 134 | 0.050 |
Why?
|
| Age Distribution | 1 | 2003 | 194 | 0.050 |
Why?
|
| Patient Selection | 1 | 2004 | 272 | 0.050 |
Why?
|
| Endpoint Determination | 2 | 2017 | 21 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 215 | 0.050 |
Why?
|
| Simplexvirus | 1 | 2002 | 3 | 0.050 |
Why?
|
| Acyclovir | 1 | 2002 | 14 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2002 | 21 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2002 | 53 | 0.040 |
Why?
|
| Fingers | 1 | 2002 | 75 | 0.040 |
Why?
|
| Face | 1 | 2020 | 29 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2020 | 11 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 44 | 0.040 |
Why?
|
| Medicine | 1 | 2020 | 36 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2020 | 44 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2019 | 34 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 60 | 0.040 |
Why?
|
| Pedigree | 1 | 2019 | 136 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 91 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 132 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2019 | 287 | 0.030 |
Why?
|
| Nasopharyngitis | 1 | 2018 | 2 | 0.030 |
Why?
|
| Dogs | 1 | 2018 | 125 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 35 | 0.030 |
Why?
|
| Fibrosis | 1 | 2018 | 126 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 167 | 0.030 |
Why?
|
| Injections | 1 | 2015 | 72 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2015 | 66 | 0.030 |
Why?
|
| Oceanic Ancestry Group | 1 | 2014 | 4 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 7 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 74 | 0.020 |
Why?
|
| Pain Threshold | 1 | 2012 | 93 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 2571 | 0.020 |
Why?
|
| Perception | 1 | 2012 | 99 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 3899 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2012 | 340 | 0.020 |
Why?
|
| Hyperandrogenism | 1 | 2010 | 2 | 0.020 |
Why?
|
| Fathers | 1 | 2010 | 12 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2010 | 75 | 0.020 |
Why?
|
| Mothers | 1 | 2010 | 74 | 0.020 |
Why?
|
| New York City | 1 | 2009 | 12 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2009 | 53 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 128 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 155 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 276 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2008 | 14 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 716 | 0.020 |
Why?
|
| Pamphlets | 1 | 2007 | 5 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2007 | 14 | 0.020 |
Why?
|
| Knowledge | 1 | 2007 | 13 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2007 | 16 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 358 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2007 | 58 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 8197 | 0.010 |
Why?
|
| Self Concept | 1 | 2006 | 45 | 0.010 |
Why?
|
| Chemexfoliation | 1 | 2004 | 2 | 0.010 |
Why?
|
| Lentigo | 1 | 2004 | 4 | 0.010 |
Why?
|
| Dicarboxylic Acids | 1 | 2004 | 6 | 0.010 |
Why?
|
| Health Status | 1 | 2007 | 356 | 0.010 |
Why?
|
| Nails | 1 | 2004 | 6 | 0.010 |
Why?
|
| Cryotherapy | 1 | 2004 | 12 | 0.010 |
Why?
|
| Helping Behavior | 1 | 2004 | 1 | 0.010 |
Why?
|
| Nursing Assessment | 1 | 2004 | 12 | 0.010 |
Why?
|
| Information Services | 1 | 2004 | 11 | 0.010 |
Why?
|
| Foundations | 1 | 2004 | 8 | 0.010 |
Why?
|
| Causality | 1 | 2004 | 37 | 0.010 |
Why?
|
| Self-Help Groups | 1 | 2004 | 11 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 650 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2004 | 55 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 179 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 1424 | 0.010 |
Why?
|
| Hair Follicle | 1 | 2004 | 7 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 36 | 0.010 |
Why?
|
| Self Care | 1 | 2004 | 97 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2003 | 44 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 702 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 138 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2004 | 138 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 237 | 0.010 |
Why?
|
| Social Support | 1 | 2004 | 181 | 0.010 |
Why?
|
| Registries | 1 | 2004 | 294 | 0.010 |
Why?
|
| Women's Health | 1 | 2004 | 230 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 2317 | 0.010 |
Why?
|